Foster Victor Wealth Advisors LLC Decreases Stake in Johnson & Johnson (NYSE:JNJ)

Foster Victor Wealth Advisors LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 32.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 71,939 shares of the company’s stock after selling 35,037 shares during the quarter. Foster Victor Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $11,557,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Regatta Capital Group LLC increased its position in Johnson & Johnson by 7.5% during the third quarter. Regatta Capital Group LLC now owns 6,684 shares of the company’s stock valued at $1,083,000 after acquiring an additional 468 shares during the last quarter. Petredis Investment Advisors LLC increased its position in Johnson & Johnson by 0.3% during the third quarter. Petredis Investment Advisors LLC now owns 38,034 shares of the company’s stock valued at $6,164,000 after acquiring an additional 118 shares during the last quarter. Ullmann Wealth Partners Group LLC increased its position in Johnson & Johnson by 29.8% during the third quarter. Ullmann Wealth Partners Group LLC now owns 6,292 shares of the company’s stock valued at $1,020,000 after acquiring an additional 1,445 shares during the last quarter. Peak Financial Management Inc. purchased a new stake in Johnson & Johnson during the third quarter valued at $231,000. Finally, RDA Financial Network increased its position in Johnson & Johnson by 1.6% during the third quarter. RDA Financial Network now owns 6,039 shares of the company’s stock valued at $979,000 after acquiring an additional 93 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $164.14 on Wednesday. The stock has a 50 day moving average of $162.70 and a 200 day moving average of $154.52. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The firm has a market cap of $395.02 billion, a PE ratio of 10.23, a PEG ratio of 2.65 and a beta of 0.52. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same period in the prior year, the company earned $2.80 earnings per share. The firm’s revenue was up 4.3% on a year-over-year basis. On average, research analysts expect that Johnson & Johnson will post 10 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of analyst reports. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. The Goldman Sachs Group reduced their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Sanford C. Bernstein upped their price target on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Thursday, October 10th. Finally, Morgan Stanley upped their price target on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. Six analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $174.31.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.